Benjamin Huang, MD

Dr. Benjamin Huang is a physician-scientist whose research program focuses on mouse cancer modeling, molecular therapeutics, and functional genomics. He is a contributing member within the UCSF Helen Diller Family Comprehensive Cancer Center, the Children's Oncology Group Myeloid Committee, and the Leukemia and Lymphoma Society Pediatric Acute Leukemia Initiative.
Education
Fellowship, 2016 - Pediatric Hematology/Oncology, University of California, San Francisco
Residency, 2013 - Pediatrics, University of California, San Francisco
M.D., 2010 - Medicine, University of California, San Francisco
B.S., 2005 - Electrical Engineering and Computer Sciences, University of California, Berkeley
Honors and Awards
  • Rally Foundation Career Development Award, 2020
  • St. Baldrick’s Foundation Scholar Award, 2020
  • Hyundai Hope on Wheels Scholar Award, 2019
  • UCSF Bleecher Young Investigator Award, 2017
  • St. Baldrick's Foundation Fellowship Award, 2016
  • UCSF School of Medicine Essential Core Teaching Award, 2010
  • Alpha Omega Alpha, Medical Honor Society, 2009
  • UC Berkeley Outstanding Graduate Student Instructor Award, 2006
  • Eta Kappa Nu, Electrical Engineering and Computer Sciences Honor Society, 2001
Websites
Publications
  1. Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia.
  2. Integrated genomic analysis identifies UBTF tandem duplications as a recurrent lesion in pediatric acute myeloid leukemia.
  3. CBFB-MYH11 Fusion Transcripts Distinguish Acute Myeloid Leukemias with Distinct Molecular Landscapes and Outcomes.
  4. Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib.
  5. Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice.
  6. Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia.
  7. Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes.
  8. Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias.
  9. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
  10. KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.
  11. Resistant T-Cell Acute Lymphoblastic Leukemias That Emerge after In Vivo Treatment with Dexamethasone Frequently Down-Regulate Glucocorticoid Receptor Protein Expression. Blood (ASH Annual Meeting Abstracts)
  12. Response and Resistance to Bromodomain Inhibition in AML Driven By Hyperactive Ras Signaling. Blood (ASH Annual Meeting Abstracts)
  13. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.